ABIN1724904
antibody from antibodies-online
Targeting: MAPK14
CSBP1, CSBP2, CSPB1, Mxi2, p38, PRKM14, PRKM15
Antibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [3]
- ELISA [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN1724904 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Mitogen-Activated Protein Kinase 14 (MAPK14) (AA 299-360) antibody
- Antibody type
- Monoclonal
- Description
- Purified
- Reactivity
- Human, Mouse, Rat, Simian
- Host
- Mouse
- Epitope
- AA 299-360
- Isotype
- IgG
- Antibody clone number
- 10B11C8
- Vial size
- 100 μg
- Storage
- 4°C, -20°C for long term storage
Submitted references Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-κB activation on endothelial cell.
Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.
Li X, Zheng Z, Li X, Ma X
Cytokine 2012 Oct;60(1):114-21
Cytokine 2012 Oct;60(1):114-21
Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.
Chung LY, Tang SJ, Sun GH, Chou TY, Yeh TS, Yu SL, Sun KH
Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Aug 1;18(15):4037-47
Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Aug 1;18(15):4037-47
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- ELISA
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC